PolyPid Ltd. (PYPD) Q3 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Polypid Ltd..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.660 Greetings, and welcome to Polypeed's third quarter 2025 00:00:04.660 -- 00:00:10.811 conference call. At this time, participants are in a listen-only mode. 00:00:10.811 -- 00:00:16.201 As a reminder, this call is recorded. And I would now like to introduce your host 00:00:16.201 -- 00:00:21.571 for today's conference, Yuda Liebler from ARX Investor Relations. 00:00:21.571 -- 00:00:24.813 Mr. Liebler, you may begin. 00:00:27.200 -- 00:00:32.627 Thank you all for participating in Polypid's third quarter 2025 earnings conference call. 00:00:32.627 -- 00:00:37.193 Joining me on the call today will be Diklan Chachkis-Akselbrad, Chief Executive Officer 00:00:37.193 -- 00:00:42.780 of Polypid, Johnny Misalawin, Polypid's Chief Financial Officer, and Ori Warshawski, 00:00:42.780 -- 00:00:48.227 Chief Operating Officer US of Polypid. Earlier today, Polypid released its financial 00:00:48.227 -- 00:00:51.911 results for the three months ended September 30th, 2025. 00:00:51.911 -- 00:00:55.921 Copy of the press release is available in the investor section on the company's website. 00:00:55.921 -- 00:00:58.361 at www.polyphys.com. 00:00:59.144 -- 00:01:02.748 I'd like to remind you that on this call, management will make forward-looking statements 00:01:02.748 -- 00:01:05.450 within the meaning of the federal securities laws. 00:01:05.450 -- 00:01:10.135 For example, management is making forward-looking statements when it discusses the anticipated 00:01:10.135 -- 00:01:15.280 timing of the pre-new drug application, or NDA, meeting of the US Food and Drug Administration, 00:01:15.280 -- 00:01:20.285 or FDA, the planned NDA submission for DPLEX-100, the expected submission of 00:01:20.285 -- 00:01:24.611 the European Marketing Authorization appl...